Search results for "LIVER TRANSPLANTATION"

showing 10 items of 359 documents

Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation

2009

Four years ago, Stangou et al. reported a patient who developed clinical symptoms of amyloidosis 8 years after domino liver transplantation (DLT). In order to alleviate the graft shortage, livers from patients with familial amyloidotic polyneuropathy (FAP) are used as domino grafts for other patients under the assumption that several decades will pass before clinical symptoms due to amyloid accumulation emerge. We now report on another case, the third reported case in the literature, of de novo systemic amyloidosis in a 75-year-old woman 9 years after DLT. The patient underwent DLT at 65 years of age for hepatocellular carcinoma exceeding the Milan criteria in hepatitis C cirrhosis. Transar…

Transplantationmedicine.medical_specialtyPathologyCirrhosisDysesthesiaHepatologybusiness.industrymedicine.medical_treatmentAmyloidosisHepatitis CLiver transplantationMilan criteriamedicine.diseaseSurgeryB symptomsMedicineSurgerymedicine.symptombusinessPolyneuropathyLiver Transplantation
researchProduct

NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options

2022

In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) represent an increasingly important underlying aetiology of hepatocellular carcinoma (HCC). HCCs arising from lipotoxicity-mediated chronic inflammation are characterised by several unique features: in contrast to virally driven HCC, up to 50% of NAFLD-HCC occurs in patients without cirrhosis and annual HCC incidence is comparatively low, complicating current surveillance strategies. On average, patients are older and are more frequently diagnosed at an advanced stage. While locoregional treatments are probably equally effective regardless of HCC aetio…

Oncologymedicine.medical_specialtyCarcinoma HepatocellularCirrhosisDiseaseType 2 diabetesNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicinemedicineHumansneoplasmsHepatologybusiness.industryLiver NeoplasmsFatty livermedicine.diseasedigestive system diseasesLiver TransplantationClinical trialTreatment OutcomeLiverHepatocellular carcinomaDisease ProgressionMetabolic syndromeSteatohepatitisbusinessJournal of Hepatology
researchProduct

Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma

2013

Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the canc…

OncologySorafenibmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationInternal medicineHepatectomyHumansMedicineChemoembolization TherapeuticPrecision MedicineEarly Detection of CancerNeoplasm StagingHepatologybusiness.industryClinical study designLiver NeoplasmsGastroenterologymedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationClinical trialTransplantationTreatment OutcomeHepatocellular carcinomaCatheter AblationLiver functionPersonalized medicinebusinessmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling

2021

Simple Summary Intrahepatic cholangiocarcinoma is a rare disease with increasing incidence and mortality still characterized by an insufficient clinical outcome. Growing attention has recently surrounded this disease, and liver transplantation has emerged as a novel curative treatment for cholangiocarcinoma, along with a better understanding of genetic alterations potentially capable of driving tumorigenesis. The aim of this paper is to present a clinical description of our case series of patients affected by intrahepatic cholangiocarcinoma and by mixed forms of hepatocellular and cholangiocellular carcinoma, together with a genomic profiling of mutations occurring in a panel of genes relev…

Cancer ResearchLiver tumorliver transplantationbusiness.industrymedicine.medical_treatmentWnt signaling pathwayCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensLiver transplantationmedicine.diseasemedicine.disease_causeArticlenext-generation sequencing.Oncologyintrahepatic cholangiocarcinomamedicineCancer researchnext-generation sequencingKRASCarcinogenesisbusinessPI3K/AKT/mTOR pathwayIntrahepatic CholangiocarcinomaRC254-282intrahepatic cholangiocarcinoma; liver transplantation; next-generation sequencingCancers
researchProduct

Leberresektionen können bei vorsichtiger Patientenselektion auch in Zirrhose sicher durchgeführt werden

2021

Zusammenfassung Hintergrund Das hepatozelluläre Karzinom (HCC) ist der häufigste maligne Lebertumor in einer Leberzirrhose. Neben der Lebertransplantation stellt die Leberresektion in kompensierter Zirrhose eine kurative Therapieoption dar, die jedoch mit einer höheren postoperativen Morbidität und Mortalität einhergeht. Patienten Es wurden 108 Patienten identifiziert, die mit einer Leberzirrhose im Zeitraum von Januar 2008 bis Dezember 2019 an der Universitätsmedizin Mainz eine Leberresektion erhalten haben. Im gleichen Zeitraum wurden 185 Resektionen wegen eines HCC in nicht zirrhotischer Leber durchgeführt. Als weitere Kontrollgruppe dienten 167 Resektionen wegen kolorektaler Lebermetast…

medicine.medical_specialtyCirrhosisbusiness.industrymedicine.medical_treatmentArea under the curvePerioperativeLiver transplantationLiver resectionsmedicine.diseaseGastroenterologyInternal medicineHepatocellular carcinomamedicineSurgeryLiver functionStage (cooking)businessZentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie
researchProduct

Intrahepatic biliary anatomy derived from right graft adult live donor liver transplantation

2008

Abstract Objective The successful management of the bile duct in right graft adult live donor liver transplantation requires knowledge of both its central (hilar) and distal (sectorial) anatomy. The purpose of this study was to provide a systematic classification of its branching patterns to enhance clinical decision-making. Patients and Methods We analyzed three-dimensional computed tomography (3-D CT) imaging reconstructions of 139 potential live liver donors evaluated at our institution between January 2003 and June 2007. Results Fifty-four (n = 54 or 38.8%) donor candidates had a normal (classic) hilar and sectorial right bile duct anatomy (type I). Seventy-eight (n = 78 or 56.1%) cases…

AdultMalemedicine.medical_specialtyLive donormedicine.medical_treatmentCholecystographyHepatic Duct CommonLiver transplantationliverImage Processing Computer-AssistedLiving DonorsmedicineHumansRetrospective StudiesTransplantationmedicine.diagnostic_testBile ductbusiness.industryGallbladderGallbladderRetrospective cohort studyMiddle AgedCholecystographyLiver TransplantationSurgeryBiliary anatomymedicine.anatomical_structureBiliary tractFemaleSurgeryTomography X-Ray Computedbusiness
researchProduct

Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis

2011

Renal function is an important predictor of survival in cirrhosis and liver transplantation. GFR estimates using serum cystatin C (CysC) are proposed as better predictors of renal function than ones on the basis of serum creatinine (Cr). Our aims were: (1) evaluate correlations between serum CysC and different methods of creatinine measurements; (2) compare CysC and Cr GFR formulas with (51)Cr-EDTA; and (3) evaluate liver-related parameters potentially influencing GFR.254 blood samples in 65 patients with cirrhosis correlating CysC with four Cr methods were used; another 74 patients comparing (51)Cr-EDTA GFR to Modification of Diet in Renal Disease and Larsson and Hoek formulas for CysC wer…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisBilirubinEpidemiologymedicine.medical_treatmentUrologyRenal functionLiver transplantationurologic and male genital diseasesCritical Care and Intensive Care MedicineAdult; Aged; Aged 80 and over; Bilirubin; Creatinine; Cystatin C; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Chromium Radioisotopes; Edetic Acid; Glomerular Filtration Rate; Nephrology; Transplantation; Epidemiology; Critical Care and Intensive Care Medicinechemistry.chemical_compoundBayesian multivariate linear regressionInternal medicine80 and overMedicineHumansCystatin CEdetic AcidAgedAged 80 and overCreatinineTransplantationbiologybusiness.industrycirrhosisBilirubinOriginal Articles51cr edta clearanceMiddle Agedmedicine.diseaseChromium RadioisotopesEndocrinologyCystatin CchemistryNephrologyCreatinineMultivariate Analysisbiology.proteinFemalebusinessGlomerular Filtration Rate
researchProduct

Characteristics, Trends, and Outcomes of Liver Transplantation for Primary Sclerosing Cholangitis in Female Versus Male Patients

2021

Background. The influence of sex on primary sclerosing cholangitis (PSC), pre- and postliver transplantation (LT) is unclear. Aims are to assess whether there have been changes in incidence, profile, and outcome in LT-PSC patients in Europe with specific emphasis on sex. Methods. Analysis of the European Liver Transplant Registry database (PSC patients registered before 2018), including baseline demographics, donor, biochemical, and clinical data at LT, immunosuppression, and outcome. Results. European Liver Transplant Registry analysis (n = 6463, 32% female individuals) demonstrated an increasing number by cohort (1980-1989, n = 159; 1990-1999, n = 1282; 2000-2009, n = 2316; 2010-2017, n =…

AdultMalemedicine.medical_specialtyTime FactorsDatabases Factualmedicine.medical_treatmentCholangitis SclerosingPopulation030230 surgeryLiver transplantationRisk AssessmentPrimary sclerosing cholangitis03 medical and health sciencesSex Factors0302 clinical medicineRisk FactorsInternal medicinemedicineHumansRegistriesHealthcare DisparitieseducationTransplantationeducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Graft SurvivalImmunosuppressionHealth Status DisparitiesMiddle Agedmedicine.diseaseLiver TransplantationEuropeTransplantationTreatment OutcomeMale patientCohortFemale030211 gastroenterology & hepatologybusinessTransplantation
researchProduct

Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.

2015

Hepatocellular carcinoma is a challenging malignancy of global importance. It is the sixth most common solid malignancy and the third leading cause of cancer-related death, worldwide. Curative treatments at early stages include liver transplantation, resection and percutaneous ablation, while transarterial chemoembolization can improve survival in patients with intermediate tumor stage. Patients with mild, related symptoms and/or macrovascular invasion or extrahepatic spread are classified under the advanced stage. The standard of care in this group is sorafenib, an inhibitor of Raf kinase and vascular endothelial growth factor receptor, whose effectiveness has been proven by 2 recent rando…

SHARPOncologyHepatocellular carcinomamedicine.medical_treatmentOLTLiver transplantationGastroenterologyLiver cirrhosilaw.inventionAntineoplastic AgentRandomized controlled triallawPractice Patterns Physicians'Randomized Controlled Trials as TopicNexavarMedicine (all)Liver NeoplasmsGastroenterologyGeneral MedicineSorafenibLocoregional therapiePercutaneous ethanol injectionLiver NeoplasmRaf kinaseHepatocellular carcinomaLiver cancerLiver cancerHumanmedicine.drugSorafenibNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsMalignancyTransarterial chemoembolizationInternal medicinemedicineCarcinomaChemotherapyHumansChemoembolization Therapeuticbusiness.industryPhenylurea CompoundsRadiofrequency ablationResectionmedicine.diseaseBCLCPercutaneous ethanol injectionbusinessDigestive diseases (Basel, Switzerland)
researchProduct

Rabbit anti-thymocyte globulin in liver transplantation: All that glitters is not gold, but 1000 patients are so many to dazzle

2012

AdultPathologymedicine.medical_specialtyBiopsymedicine.medical_treatmentLiver transplantationEnd Stage Liver DiseaseRecurrenceBiopsyAnimalsHumansMedicineAntilymphocyte SerumClinical Trials as TopicTransplantationHepatologymedicine.diagnostic_testbusiness.industryCase-control studyEnd stage liver diseaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CLiver TransplantationAnti-thymocyte globulinCase-Control StudiesImmunologySurgeryRabbitsbusinessImmunosuppressive AgentsLiver Transplantation
researchProduct